Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
66.82
-1.27 (-1.87%)
At close: Sep 4, 2026, 4:00 PM EDT
67.00
+0.18 (0.27%)
After-hours: Sep 4, 2026, 7:56 PM EDT
Bristol-Myers Squibb Company Employees
Bristol-Myers Squibb Company had 32,500 employees as of December 31, 2025. The number of employees decreased by 1,600 or -4.69% compared to the previous year.
Employees
32,500
Change (1Y)
-1,600
Growth (1Y)
-4.69%
Revenue / Employee
$1,513,415
Profits / Employee
$285,600
Market Cap
136.49B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 32,500 | -1,600 | -4.69% |
| Dec 31, 2024 | 34,100 | 0 | - |
| Dec 31, 2023 | 34,100 | -200 | -0.58% |
| Dec 31, 2022 | 34,300 | 2,100 | 6.52% |
| Dec 31, 2021 | 32,200 | 1,950 | 6.45% |
| Dec 31, 2020 | 30,250 | 250 | 0.83% |
| Dec 31, 2019 | 30,000 | 6,700 | 28.76% |
| Dec 31, 2018 | 23,300 | -400 | -1.69% |
| Dec 31, 2017 | 23,700 | -1,300 | -5.20% |
| Dec 31, 2016 | 25,000 | 0 | - |
| Dec 31, 2015 | 25,000 | 0 | - |
| Dec 31, 2014 | 25,000 | -3,000 | -10.71% |
| Dec 31, 2013 | 28,000 | 0 | - |
| Dec 31, 2012 | 28,000 | 1,000 | 3.70% |
| Dec 31, 2011 | 27,000 | 0 | - |
| Dec 31, 2010 | 27,000 | -1,000 | -3.57% |
| Dec 31, 2009 | 28,000 | -7,000 | -20.00% |
| Dec 31, 2008 | 35,000 | -7,000 | -16.67% |
| Dec 31, 2007 | 42,000 | -1,000 | -2.33% |
| Dec 31, 2006 | 43,000 | 0 | - |
| Dec 31, 2005 | 43,000 | 0 | - |
| Dec 31, 2004 | 43,000 | -1,000 | -2.27% |
| Dec 31, 2003 | 44,000 | 0 | - |
| Dec 31, 2002 | 44,000 | -2,000 | -4.35% |
| Dec 31, 2001 | 46,000 | 2,000 | 4.55% |
| Dec 31, 2000 | 44,000 | -10,500 | -19.27% |
| Dec 31, 1999 | 54,500 | -200 | -0.37% |
| Dec 31, 1998 | 54,700 | 1,100 | 2.05% |
| Dec 31, 1997 | 53,600 | 2,400 | 4.69% |
| Dec 31, 1996 | 51,200 | 2,060 | 4.19% |
| Dec 31, 1995 | 49,140 | 1,440 | 3.02% |
| Dec 31, 1994 | 47,700 | -1,800 | -3.64% |
| Dec 31, 1993 | 49,500 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Merck & Co. | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
BMY News
- 3 days ago - Drugmakers quietly halted autoimmune drug trials because of deaths or problematic side effects, raising questions about disclosure around experimental research - WSJ
- 3 days ago - Eikon Therapeutics appoints Ching-Pin Chang as chief scientific officer - TheFly
- 3 days ago - Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services - Barrons
- 7 days ago - Bristol Myers presents results for EXPLORER-LTE cohort of MAVA-LTE study - TheFly
- 8 days ago - Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026 - Business Wire
- 12 days ago - Bristol Myers Squibb Stock (BMY) Looks Healthier After Ditching Blood Cancer Partner - TipRanks
- 12 days ago - Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares - Reuters
- 17 days ago - Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery - Business Wire